Inhibitors of ACK1/TNK2 tyrosine kinase
Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.
1. A compound having Formula IA:
wherein
R 1 is Cl, Br, F, CH 3 , or C 2 H 5 ;
m is 1 or 2; and
at least one R 4 is a cycloalkyl or heterocycloalkyl that is unsubstituted or substituted with R 6 , and, if present, the other R 4 is OH, Cl, Br, F, C 1 -C 6 alkyl, CN, NO 2 , or OR 5 where
R 5 is C 1 -C 6 alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl; and
R 6 is OH, Cl, Br, F, C 1 -C 6 alkyl, CO 2 H, CO 2 R 5 , OC(O)R 5 , (CH 2 ) 1-6 CO 2 H, C(O)(CH 2 ) 1-6 CO 2 H, (CH 2 ) 1-6 CO 2 R 5 , C(O)(CH 2 ) 1-6 CO 2 R 5 , OR 5 , C(O)R 5 , C(O)NH 2 , C(O)NHR 5 , SO 2 NH 2 , SO 2 NHR 5 , C(O)NHSO 2 R 5 , 4-morpholinyl, 4-piperazinyl, 1-piperidinyl, 4-piperadinyl group, or PEG-sterol,
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein R 1 is Cl or Br.
3. The compound of claim 1 , wherein m is 1 and R 4 is 4-morpholinyl, 4-piperazinyl, 1-piperidinyl, or 4-piperadinyl group that is unsubstituted or substituted with R 6 .
4. The compound of claim 1 , wherein m is 1 and R 4 is in the para position or m is 2 and each R 4 are in the para and meta positions.
5. The compound of claim 1 chosen from
6. The compound of claim 1 , wherein the compound is